共 115 条
[1]
Manns MP(1999)Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium J Viral Liver 6 34-5
[2]
McHutchison JG(2001)Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 958-965
[3]
Gordon SC(2004)Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 346-355
[4]
Hadziyannis SJ(2010)Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis: a retrospective study in 507 patients J Gastrointestin Liver Dis 19 261-264
[5]
Sette H(2012)High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials Hepatology 56 2039-2050
[6]
Morgan TR(2011)Response to standard of care antiviral treatment in patients with HCV liver cirrhosis: a systematic review J Gastrointestin Liver Dis 20 293-298
[7]
Sporea I(2008)Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh A liver cirrhosis Scand J Gastroenterol 43 1378-1386
[8]
Sirli R(2010)PegInterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response Am J Gastroenterol 105 2164-2172
[9]
Curescu M(2010)Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study Gastroenterology 138 1338-45
[10]
Marcellin P(2010)Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection Hepatology 52 1216-24